Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1010 versus Influsplit Tetra in adults aged 50 years and older
2024-516240-26-00Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 11
01
Overview
Phase 3, randomised, single-blind trial in influenza comparing mRNA-1010 with Influsplit Tetra active control (2 arms). Primary endpoints: Solicited local and systemic adverse reactions, Unsolicited adverse events and 2 more. Started Sep 2024; status: completed.
02
Drugs
mRNA-1010Influsplit
03
Conditions
influenza
Beyond the preview
Go deeper on 2024-516240-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516240-26-00.